XML 39 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
Balance Sheet Components
12 Months Ended
Dec. 31, 2018
Balance Sheet Related Disclosures [Abstract]  
Balance Sheet Components
Balance Sheet Components

Inventories

Inventories consist of the following (in thousands): 
 
December 31,
 
2018
 
2017
Raw materials
$
26,119

 
$
12,721

Work in process
13,784

 
12,157

Finished goods
15,738

 
6,810

Total inventories
$
55,641

 
$
31,688



Other Assets

Other assets consist of the following (in thousands): 
 
December 31,
 
2018
 
2017
Capitalized commissions 1
$
9,185

 
$
5,514

Equity securities
9,862

 

Security deposits
5,162

 
3,557

Loan receivable from equity investee

 
30,000

Other long-term assets
2,778

 
4,822

Total other assets
$
26,987

 
$
43,893



(1) December 31, 2017 balance has been recasted to reflect the adoption of ASU 2014-09 (Refer to Note 1“Summary of Significant Accounting Policies” of the Notes to Consolidated Financial Statements for more information).


Property, Plant and Equipment, Net

Property, plant and equipment consist of the following (in thousands):
 
 
 
December 31,
 
Generally Used Estimated Useful Life
 
2018
 
2017
Clinical and manufacturing equipment
Up to 10 years
 
$
236,179

 
$
183,392

Computer hardware
3 years
 
34,297

 
24,933

Computer software
3 years
 
59,617

 
54,756

Furniture and fixtures
5 years
 
33,436

 
16,271

Leasehold improvements
Lease term (1)
 
77,168

 
37,756

Building
20 years
 
139,315

 
63,887

Land
 
17,630

 
17,630

CIP
 
95,414

 
85,976

Total
 
 
693,056

 
484,601

Less: Accumulated depreciation and amortization and impairment charges
 
 
(171,727
)
 
(135,808
)
Total property, plant and equipment, net
 
 
$
521,329

 
$
348,793



(1) Shorter of remaining lease term or estimated useful lives of asset

Depreciation and amortization was $54.7 million, $37.7 million and $24.0 million for the year ended December 31, 2018, 2017 and 2016, respectively.

Accrued Liabilities

Accrued liabilities consist of the following (in thousands): 
 
December 31,
 
2018
 
2017
Accrued payroll and benefits
$
127,109

 
$
103,004

Accrued expenses
39,323

 
27,318

Accrued customer credits and deposits
12,439

 
5,373

Accrued warranty
8,551

 
5,929

Accrued property, plant and equipment
8,193

 
11,362

Accrued professional fees
6,752

 
6,316

Accrued sales return reserve 1
6,534

 
1,364

Accrued sales tax and value added tax
6,276

 
5,503

Accrued income taxes
5,752

 
12,405

Accrued sales rebate
5,668

 
11,209

Other accrued liabilities
8,082

 
5,779

Total accrued liabilities
$
234,679

 
$
195,562



(1) December 31, 2017 balance has been reclassified from accounts receivable, net to reflect the adoption of ASU 2014-09 (Refer to Note 1 “Summary of Significant Accounting Policies” of the Notes to Consolidated Financial Statements for more information).

Warranty

We regularly review the balance for accrued warranty and update based on historical warranty trends. Actual warranty costs incurred have not materially differed from those accrued; however, future actual warranty costs could differ from the estimated amounts.


Warranty as of December 31, 2018 and 2017 consists of the following activity (in thousands):
 
Accrued warranty as of December 31, 2016
$
3,841

Charged to cost of net revenues
7,195

Actual warranty expenditures
(5,107
)
Accrued warranty as of December 31, 2017
5,929

Charged to cost of net revenues
15,059

Actual warranty expenditures
(12,437
)
Accrued warranty as of December 31, 2018
$
8,551



Deferred Revenues

Deferred revenues consist of the following (in thousands):
 
December 31,
 
2018
 
2017
Deferred revenues - current
$
393,138

 
$
267,713

Deferred revenues - long-term 1
17,051

 
4,588


1 Included in other long-term liabilities within our Consolidated Balance Sheet

During the year ended December 31, 2018 and 2017, we recognized $2.0 billion and $1.5 billion of revenue, respectively, of which $180.6 million and $119.0 million was included in the deferred revenues balance at December 31, 2017 and December 31, 2016, respectively.